RxDoctor Payments DataLook up a doctor →

Mahmood Moosa, MD

Endocrinology, Diabetes & Metabolism · Monroe, MINPI 1669478681

Payments from drug & device makers

$15,770in general payments, 2019–2025

Across 1,114 payments — averaging $14.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • Amgen$1K
  • Xeris Pharmaceuticals, Inc.$883
  • Dexcom, Inc.$873
  • Boehringer Ingelheim$801
  • plus $8K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk217$2,055
Lilly USA, LLC123$1,707
Amgen(2 entities)72$1,074
Xeris Pharmaceuticals, Inc.45$883
Dexcom, Inc.84$873
Boehringer Ingelheim48$801
Amarin Pharma, Inc.56$644
Sanofi-aventis U.S. LLC44$593
AstraZeneca(2 entities)36$578
Antares Pharma, Inc.28$487
Novartis25$473
Tandem Diabetes Care, Inc.16$372
Corcept Therapeutics17$332
Abbott23$296
Merck26$263
Recordati_rare_diseases_inc.15$256
AbbVie15$251
Medtronic(2 entities)16$231
Johnson & Johnson20$224
Ascendis Pharma Endocrinology Inc11$217
Shire North American Group Inc12$217
Ascensia Diabetes Care US Inc.10$207
Mannkind Corporation10$205
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$156
BD8$133
Acella Pharmaceuticals, LLC7$127
Vivus LLC7$126
Radius Health, Inc.8$124
Sequel Med Tech, LLC6$119
Amneal Pharmaceuticals LLC7$115
Esperion Therapeutics, Inc.7$108
Neurocrine Biosciences, Inc.4$105
Bayer6$104
Nevro Corp.4$104
Tolmar, Inc.6$104
Lifescan, Inc.5$94
Regeneron Healthcare Solutions, Inc.5$91
Halozyme Inc5$88
Insulet Corporation4$71
Zealand Pharma US, Inc.3$70
Kyowa Kirin, Inc.3$62
IBSA Pharma Inc.4$58
Ultragenyx Pharmaceutical Inc.3$55
Cequr Corporation4$48
Vifor Pharma, Inc.1$44
BETA Bionics, Inc.3$42
Amphastar Pharmaceuticals, Inc.2$37
Embecta Corp.2$35
GRT US Holding, Inc.2$28
Checkpoint Surgical, Inc1$27
Verity Pharmaceuticals Inc.1$24
Currax Pharmaceuticals LLC2$23
Rhythm Pharmaceuticals, Inc.1$19
Astellas Pharma US Inc1$19
Boston Scientific1$19
Acerus Pharmaceuticals Corporation1$18
EUSA Pharma (US) LLC1$17
Ipsen Biopharmaceuticals, Inc1$17
Averitas Pharma Inc.1$17
Azurity Pharmaceuticals, Inc.1$15

How this compares

$15,770 in reported general payments places this provider in the 80th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan →

Medicare billing

Part B allowed, 2024
$270,807
Medicare patients
798
Services billed
3,131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Monroe

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →